NCT00038220
Completed
Phase 2
A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Abbott
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Proportion of subjects in each group demonstrating complete suppression of viral replication at Week 144.
Overview
Brief Summary
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have HIV Infection.
- •Age 18 to 65 years old.
- •Show no signs of recent illness other than HIV infection.
- •Agree to use a barrier method of birth control during the study and for 30 days after study.
Exclusion Criteria
- •Are unable to follow study requirements (in the opinion of the investigator).
- •Are pregnant or breast-feeding.
- •Are unable to take medications by mouth.
- •Have chronic nausea or vomiting.
- •Have cancer other than Kaposi's sarcoma or basal cell carcinoma.
- •Have active, serious infections (other than HIV) requiring antibiotic injections within 15 days prior to screening.
- •Are taking any medications that are not allowed with ABT-378/r and efavirenz.
- •Are taking or have taken any other experimental drugs, antiretroviral drugs, or drugs that affect the immune system within 30 days of start of study without consent of the medical monitor.
- •Are receiving or have received radiation therapy within 30 days of start of study without consent of the medical monitor.
- •Have a history of drug abuse or mental illness that would prevent the patient from following the protocol requirements.
Outcomes
Primary Outcomes
Proportion of subjects in each group demonstrating complete suppression of viral replication at Week 144.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected AdultsHIV InfectionsNCT00004585Glaxo Wellcome40
Terminated
Phase 2
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002418Bristol-Myers Squibb25
Completed
Phase 2
A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionHIV InfectionsNCT00002233Glaxo Wellcome30
Completed
Phase 2
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination TherapyHIV InfectionsNCT00004985Agouron Pharmaceuticals75
Completed
Phase 3
Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease InhibitorHIV InfectionsNCT00041769National Institute of Allergy and Infectious Diseases (NIAID)360